LC
IMNM icon

Lindbrook Capital’s Immunome IMNM Stock Holding History

Lindbrook Capital’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$686 Buy
+102
New +$979 ﹤0.01% 2548
2024
Q4 		– Sell
-38
Closed -$556 – 2844
2024
Q3 		$556 Sell
38
-15
-28% -$213 ﹤0.01% 2638
2024
Q2 		$641 Buy
+53
New +$829 ﹤0.01% 2565
2021
Q4 		– Sell
-1,000
Closed -$24K – 2138
2021
Q3 		$24K Buy
+1,000
New +$17.4K 0.01% 680

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Lindbrook Capital's IMNM Position: Q1 2025 in Review

Lindbrook Capital opened a new position in Immunome (IMNM) in Q1 2025: 102 shares worth $686. The stake represents ﹤0.01% of the portfolio and ranks #2548 among its holdings. This is a return to the name: Lindbrook Capital previously reported a position in IMNM as recently as Q3 2024.

Lindbrook Capital first reported a position in IMNM in Q3 2021 and has held it in 4 quarters since. The position peaked at $24K in Q3 2021. 142 funds tracked by Wall St. Rank hold IMNM as of Q1 2025.

  • Lindbrook Capital held 102 shares of Immunome worth $686 as of Q1 2025.
  • Immunome was a new Lindbrook Capital position in Q1 2025.
  • Immunome made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2548 holding.
  • Lindbrook Capital first reported a position in Immunome in Q3 2021 and has held it in 4 quarters since.
  • Lindbrook Capital's Immunome position peaked at $24K in Q3 2021.
  • 142 funds tracked by Wall St. Rank held Immunome as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.